| pubmed-article:19820037 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0023977 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0733758 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0039601 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0066928 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C1412384 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0971174 | lld:lifeskim |
| pubmed-article:19820037 | lifeskim:mentions | umls-concept:C0121902 | lld:lifeskim |
| pubmed-article:19820037 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19820037 | pubmed:dateCreated | 2009-12-18 | lld:pubmed |
| pubmed-article:19820037 | pubmed:abstractText | Medical castration with long-acting GnRH-agonist (GnRHa) is a well-established treatment for metastatic prostate cancer. Our aim was to explore the relationships between FSH, inhibin B, anti-Mullerian hormone (AMH), and testosterone during treatment with an implant releasing GnRHa. | lld:pubmed |
| pubmed-article:19820037 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19820037 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19820037 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19820037 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19820037 | pubmed:issn | 1479-683X | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:ChertinBorisB | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:FarkasAmicurA | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:SpitzIrving... | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:Eldar-GevaTal... | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:MargaliothEhu... | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:FridmansAlonA | lld:pubmed |
| pubmed-article:19820037 | pubmed:author | pubmed-author:LibertyGadG | lld:pubmed |
| pubmed-article:19820037 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19820037 | pubmed:volume | 162 | lld:pubmed |
| pubmed-article:19820037 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19820037 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19820037 | pubmed:pagination | 177-81 | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:meshHeading | pubmed-meshheading:19820037... | lld:pubmed |
| pubmed-article:19820037 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19820037 | pubmed:articleTitle | Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. | lld:pubmed |
| pubmed-article:19820037 | pubmed:affiliation | Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, The Hebrew University, Jerusalem, Israel. gevat@szmc.org.il | lld:pubmed |
| pubmed-article:19820037 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19820037 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19820037 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
